title: Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
abstract: BACKGROUND
  Breast cancer is the most common cancer in female population. Breast cancer chemotherapy using doxorubicin (DOX) is well illustrated. However, a significant obstacle for successful chemotherapy with DOX is multidrug resistant (MDR) in breast cancer cells. Targeted nanocarriers have emerged as frontier research for the improvement of cancer chemotherapy.
  
  
  OBJECTIVE
  Bombesin (Bn)-modified, DOX-loaded solid lipid nanoparticles (Bn-DOX/SLNs) were constructed. Doxorubicin-resistant MCF-7/MDR human breast cancer cells and the cancer animal models were applied for the evaluation of the in vitro and in vivo anti-tumor effect of Bn-DOX/SLNs.
  
  
  METHODS
  Bn-conjugated lipids were synthesized. DOX was then loaded into Bn-modified SLNs. The physicochemical properties of the Bn-DOX/SLNs were investigated by particle size and zeta potential measurement, drug loading and drug-entrapment efficiency, and in vitro drug release behavior. In vitro cytotoxicity against MCF-7/MDR cells was investigated, and in vivo anti-tumor of SLNs was evaluated in human breast cancer mice models.
  
  
  RESULTS
  Bn-DOX/SLNs showed an excellent in vitro cytotoxicity and in vivo anti-tumor effect both in MCF-7/MDR breast cancer cells and breast cancer animal model.
  
  
  CONCLUSIONS
  The results demonstrated that Bn-DOX/SLNs reversed the resistance of doxorubicin, suggesting that chemotherapy using this kind of targeted nanocarriers may benefit human breast MDR cancer therapy.
authors.affiliation: a Department of Breast Surgery , Weifang People's Hospital , Weifang , Shandong , China.
authors.forename: Changliang
authors.initials: C
authors.lastname: Wang
authors.affiliation: a Department of Breast Surgery , Weifang People's Hospital , Weifang , Shandong , China.
authors.forename: Xianglian
authors.initials: X
authors.lastname: Sun
authors.affiliation: a Department of Breast Surgery , Weifang People's Hospital , Weifang , Shandong , China.
authors.forename: Kai
authors.initials: K
authors.lastname: Wang
authors.affiliation: a Department of Breast Surgery , Weifang People's Hospital , Weifang , Shandong , China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.affiliation: a Department of Breast Surgery , Weifang People's Hospital , Weifang , Shandong , China.
authors.forename: Fuqian
authors.initials: F
authors.lastname: Yang
authors.affiliation: a Department of Breast Surgery , Weifang People's Hospital , Weifang , Shandong , China.
authors.forename: Huidong
authors.initials: H
authors.lastname: Wang
mesh_terms: D000818:Animals; D001839:Bombesin / Q000737:chemistry*; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry*; D018432:Drug Resistance, Multiple / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006801:Humans; D008055:Lipids / Q000737:chemistry; D061986:MCF-7 Cells; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D010455:Peptides / Q000737:chemistry*
chemical_list: D004337:Drug Carriers; D008055:Lipids; D010455:Peptides; D004317:Doxorubicin; D001839:Bombesin
keywords: Bombesin modified; breast cancer; doxorubicin; solid lipid nanoparticles; targeted chemotherapy